Trial · NCT01509677
Registered outcomes33
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 33
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of CD8+ Inflammatory Cells in Bronchial Biopsy Tissue. | 16 weeks | |
| Primary | Change in Number of CD8+ Inflammatory Cells in Bronchial Biopsy Tissue | Baseline to 16 weeks | |
| Secondary | CD68+ Count in Biopsied Material (Submucosa) | 16 weeks | |
| Secondary | CD68+ Cell Count in Biopsied Material (Submucosa): Poisson Regression (Ratio) | 16 weeks | CD68+ Cell Count in Biopsied Material (submucosa): Poisson regression (ratio). Clarification: Measure type described as "Number" refers to "Risk of each treatment group". It is not possible to select "risk" from this template so "number" was selected instead. This issue applies to similar variables reporting poisson regression. |
| Secondary | Change From V2 to V6 in CD68+ Cell Count (Cells/mm^2) in Biopsied Material (Submucosa) (ITT) | Baseline and 16 weeks | |
| Secondary | CD4+ Cell Counts in Biopsied Material (Submucosa):Poisson Regression Model | 16 weeks | CD4+ Cell Counts in biopsied Material (submucosa):poisson regression model. Clarification: Measure type "Number" refers to "Risk of each treatment group". |
| Secondary | CD45+ Cell Counts in Biopsied Material (Submucosa):Poisson Regression Model | 16 weeks | CD45+ Cell Counts in biopsied Material (submucosa):poisson regression model. Clarification: Measure type "Number" refers to "treatment risk" |
| Secondary | Neutrophils Cell Counts in Biopsied Material (Submucosa):Poisson Regression Model | Baseline to 14 weeks | Neutrophils Cell Counts in biopsied Material (submucosa):poisson regression model. Clarification: Measure type "Number" refers to "Treatment risk" |
| Secondary | CD8+ Cell Count in Biopsied Material (Bronchial Epithelium): Poisson Regression Model | 16 weeks | CD8+ Cell Count in biopsied material (Bronchial Epithelium): poisson regression model. Clarification: Measure Type "Number" refers to "Treatment risk" |
| Secondary | CD68+ Cell Count in Biopsied Material (Bronchial Epithelium):Poisson Regression Model | 16 weeks | CD68+ Cell Count in biopsied material (Bronchial Epithelium):poisson regression model. Clarification: Measure type "Number" refers to "Treatment Risk" |
| Secondary | Change From V1 to V5 in Absolute Cell Count in Induced Sputum (10^6 Neutrophils/mL): Between-Treatment Difference | Baseline to 14 weeks | |
| Secondary | Change From V1 to V5 in Absolute Cell Count inInduced Sputum (10^6 Macrophages/mL): Between-Treatment Difference | Baseline to 14 weeks | |
| Secondary | Change From V1 to V5 in Absolute Cell Count inInduced Sputum (10^6 Eosinophils/mL): Between-Treatment Difference | Baseline to 14 weeks | |
| Secondary | Change From V1 to V5 in Absolute Cell Count inInduced Sputum (10^6 Lymphocytes/mL): Between-Treatment Difference | BAseline to 14 weeks | |
| Secondary | Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Neutrophils/mL) | Baseline to 14 weeks | |
| Secondary | Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Macrophages/mL) | Baseline to 14 weeks | |
| Secondary | Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Eosinophils/mL) | Baseline to 14 weeks | |
| Secondary | Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Lymphocytes)/mL) | Baseline to 14 weeks | |
| Secondary | Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (Alfa- 2-Macroglobulin (µg/mL)) | Baseline to 14 weeks | |
| Secondary | Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (IL-8 (pg/mL)) | Baseline to 14 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01509677/registered